Ron Wald1,2, Christian G Rabbat3, Louis Girard4, Amit X Garg5, Karthik Tennankore6, Jessica Tyrwhitt7, Andrew Smyth7, Andrea Rathe-Skafel8, Peggy Gao7, Andrea Mazzetti7, Jackie Bosch7, Andrew T Yan2,9, Patrick Parfrey10, Braden J Manns4,11, Michael Walsh3,7. 1. Divisions of Nephrology and waldr@smh.ca. 2. Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada. 3. Division of Nephrology, McMaster University, Hamilton, Ontario, Canada. 4. Department of Medicine and Libin Cardiovascular Institute and. 5. Division of Nephrology, Western University, London, Ontario, Canada. 6. Division of Nephrology, Dalhousie University, Halifax, Nova Scotia, Canada. 7. Population Health Research Institute, Hamilton, Ontario, Canada; and. 8. Divisions of Nephrology and. 9. Cardiology, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada. 10. Division of Nephrology, Memorial University, St. John's, Newfoundland, Canada. 11. Department of Community Health Sciences and the Institute of Public Health, University of Calgary, Calgary, Alberta, Canada.
Abstract
BACKGROUND AND OBJECTIVES: Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized controlled trial of prevalent hemodialysis recipients already receivingcalcium carbonateas a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33-4.66 mg/dl (0.75-1.50 mmol/L) or a liberalized target of 6.20-7.75 mg/dl (2.00-2.50 mmol/L) by titrating calcium carbonate using a dosing nomogram. The primary outcome was the difference in the change in serum phosphate from randomization to 26 weeks. RESULTS:Fifty-three participants were randomized to the intensive group and 51 to the liberalized group. The median (interquartile range) daily dose of elemental calcium at 26 weeks was 1800 (1275-3000) mg in the intensive group, and 0 (0-500) mg in the liberalized group. The mean (SD) serum phosphate at 26 weeks was 4.53 (1.12) mg/dl (1.46 [0.36] mmol/L) in the intensive group and 6.05 (1.40) mg/dl (1.95 [0.45] mmol/L) in the liberalized group. Phosphate concentration in the intensive group declined by 1.24 (95% confidence interval, 0.75 to 1.74) mg/dl (0.40 [95% confidence interval, 0.24 to 0.56] mmol/L) compared with the liberalized group. There were no statistically significant differences between the two groups in the risk of hypercalcemia, hypocalcemia, parathyroidectomy, or major vascular events. CONCLUSIONS: It is feasible to achieve and maintain a difference in serum phosphate concentrations in hemodialysis recipients by titrating calcium carbonate. A large trial is needed to determine if targeting a lower serum phosphate concentration improves patient-important outcomes.
RCT Entities:
BACKGROUND AND OBJECTIVES:Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized controlled trial of prevalent hemodialysis recipients already receiving calcium carbonate as a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33-4.66 mg/dl (0.75-1.50 mmol/L) or a liberalized target of 6.20-7.75 mg/dl (2.00-2.50 mmol/L) by titrating calcium carbonate using a dosing nomogram. The primary outcome was the difference in the change in serum phosphate from randomization to 26 weeks. RESULTS: Fifty-three participants were randomized to the intensive group and 51 to the liberalized group. The median (interquartile range) daily dose of elemental calcium at 26 weeks was 1800 (1275-3000) mg in the intensive group, and 0 (0-500) mg in the liberalized group. The mean (SD) serum phosphate at 26 weeks was 4.53 (1.12) mg/dl (1.46 [0.36] mmol/L) in the intensive group and 6.05 (1.40) mg/dl (1.95 [0.45] mmol/L) in the liberalized group. Phosphate concentration in the intensive group declined by 1.24 (95% confidence interval, 0.75 to 1.74) mg/dl (0.40 [95% confidence interval, 0.24 to 0.56] mmol/L) compared with the liberalized group. There were no statistically significant differences between the two groups in the risk of hypercalcemia, hypocalcemia, parathyroidectomy, or major vascular events. CONCLUSIONS: It is feasible to achieve and maintain a difference in serum phosphate concentrations in hemodialysis recipients by titrating calcium carbonate. A large trial is needed to determine if targeting a lower serum phosphate concentration improves patient-important outcomes.
Authors: Suetonia C Palmer; Sharon Gardner; Marcello Tonelli; Dimitris Mavridis; David W Johnson; Jonathan C Craig; Richard French; Marinella Ruospo; Giovanni F M Strippoli Journal: Am J Kidney Dis Date: 2016-07-22 Impact factor: 8.860
Authors: Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz Journal: Toxins (Basel) Date: 2018-06-12 Impact factor: 4.546
Authors: Ramya Bhargava; Philip A Kalra; Mark Hann; Paul Brenchley; Helen Hurst; Alastair J Hutchison Journal: BMC Nephrol Date: 2019-02-04 Impact factor: 2.388
Authors: Marcelo Barreto Lopes; Angelo Karaboyas; Brian Bieber; Ronald L Pisoni; Sebastian Walpen; Masafumi Fukagawa; Anders Christensson; Pieter Evenepoel; Marisa Pegoraro; Bruce M Robinson; Roberto Pecoits-Filho Journal: Nephrol Dial Transplant Date: 2020-10-01 Impact factor: 5.992